6 TECH OUTLOOKNovember - 2018Copyright © 2018 ValleyMedia Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.NOVEMBER - 30 - 2018, Vol 02 - 11 Published by ValleyMedia Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.comEditor-in-ChiefStacey SmithSalesVisualizerAsher BlakeJohn GouthamEditorial StaffAaron Pierce Ashik Jain Ava GarciaJenna Vegas Joshua ParkerJustin SmithJennifer Stephen Jennifer@pharmatechoutlook.comPhone: 510.996.5173EditorialStacey SmithEditor-in-Chiefeditor@pharmatechoutlook.comOver the last decade, the caricature of clinical trials has witnessed profound changes owing to stringent regulations and growing costs during drug developments. Amidst these transformations, clinical trails' today captures humungous amount of data which were previously generated through paper trials. The primary problem that lingers with paper trials are that they are difficult to handle and managing them brings forth additional financial burdens on CROs. In this mix, organizations are now shifting towards digital documentation of clinical trials which enables them to maintain records feasibly and cost-effectively. Further, CROs are also working to create a global synchronized database that will allow any medical organizations or concerned authorities to retrieve data from any location. The emergence of several nascent technologies and the rise of clinical grade wearables, smartphone applications, computer vision, and cloud computing has further triggered the technological advancements in clinical research. For instance, big data and blockchain technology are enabling CROs to optimize data quality and adopt a unified approach for capturing and storing data. These radical advancements enable CROs to access new compounds and resources and bring profound changes in their existing nomenclature of clinical trials. Conversely, the democratization of CROs has also put immense pressure on the industry to develop innovative machines that can reduce the costs during clinical trials. The problem further fuels when technology-enabled clinical trials have to adhere with the ever-changing and stringent regulatory directives. To assist industry leaders to maneuver in the right direction while looking for CROs, our distinguished editorial panel at Pharma Tech Outlook have analyzed the different emerging trends in the CRO space to filter out solutions that are genuinely crafted for this space, outperform others, and can solve the imperative challenges prevailing in the industry. This edition of our magazine is a result of our commitment to stick to our mission. We bring you the "Top 10 CROs in Europe - 2018." Please let us know your thoughts. The Promise of DigitalTECH OUTLOOKTECH OUTLOOK*Some of the Insights are based on the interviews with respective CIOs andCXOs to our editorial staffNOVEMBER - 30 - 2018CROs EUROPE SPECIALsales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Contact Us:Phone:510.556.2402, Fax:510-894-8405
< Page 5 | Page 7 >